Sandostatin Ineffective in Preventing Diarrhea in Anal and Rectal Cancer Patients Treated with Chemoradiotherapy (03/30/2010)
Sandostatin® (ocreotide acetate) does not prevent diarrhea in patients with anal or rectal cancer treated with chemotherapy and radiation therapy. The results of this randomized, double-blind, placebo controlled trial were recently reported in the Journal of the National Cancer Institute.

Immunosuppression Increases Risk of HPV-related Cancers in AIDS Patients (08/20/2009)
The risk of HPV-related cancers is elevated among AIDS patients. This risk continues to increase as patients’ immune systems become more compromised, according to the results of a study published in the Journal of the National Cancer Institute.

No Benefit with Addition of Platinol® to Treatment for Anal Cancer (05/01/2008)
Addition of the drug Platinol® (cisplatin) to 5-FU (5-flourouracil), mitomycin, and radiation may not improve outcomes for patients with anal cancer. These findings were recently published by the Journal of the American Medical Association.

Women with CIN at Higher Risk for Anal Cancer and Other Cancers (03/22/2007)
According to an early online publication in Lancet Oncology, women diagnosed with cervical intraepithelial neoplasia (CIN) grade 3 are at an increased risk of developing vaginal, vulvar, and anal cancers. Further research into the impact of the human papillomaviruses on these risks is underway.

5-FU/Mitomycin Remains Standard of Care for Anal Cancer (07/26/2006)
According to results recently reported at the 2006 semi-annual meeting of the Radiation Therapy Oncology Group (RTOG), treatment including the chemotherapy agents 5-fluorouracil and mitomycin-C (Mutomycin®) plus radiation therapy remains the standard of care for patients with anal cancer.

Radiation to the Pelvis Increases Risk of Pelvic Fractures (11/28/2005)
According to a recent article published in the Journal of the American Medical Association (JAMA), women who undergo radiation to the pelvis for cancers of the cervix, rectum, or anus are at an increased risk for pelvic fractures compared to women with these types of cancer who do not undergo pelvic radiation as part of their treatment regimen.

Recurrent

Screening/Prevention

Stage IV

Stages I-II